N-methyl-D-aspartate antagonists and drug discrimination

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 2, 1999, Pages 275-281

  Koek, Wouter ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Drug discrimination; NMDA antagonists; Phencyclidine

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; AMANTADINE; APTIGANEL; CYCLAZOCINE; DIZOCILPINE; ELIPRODIL; EXCITATORY AMINO ACID; FENTANYL; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IBOGAINE; IFENPRODIL; KETAMINE; LAMOTRIGINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; RECEPTOR SUBTYPE; RILUZOLE;

BRAIN ISCHEMIA; CONFERENCE PAPER; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; EPILEPSY; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; DISCRIMINATION (PSYCHOLOGY); EXCITATORY AMINO ACID AGONISTS; HUMANS; N-METHYLASPARTATE; PHENCYCLIDINE;

EID: 0032878767     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00055-6     Document Type: Conference Paper

References (67)

1. Albers G.W., Clark W.M., Atkinson R.P., Madden K., Barbut D., Lechtenberg R., Whitehouse M.J. Dose escalation study of the NMDA glycine-site antagonist ACEA 1021 in acute ischemic stroke. Stroke. 28:1997;233.
2. Balster R.L., Mansbach R.S., Shelton K.L., Nicholson K.L., Grech D.M., Wiley J.L., Li H., Weber E. Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav. Pharmacol. 6:1995;577-589.
3. Balster R.L., Nicholson K.L., Sanger D.J. Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats. Drug Alcohol Depend. 35:1994;211-216.
4. Baron S.P., Woods J.H. Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons. CGS 19755 and phencyclidine Psychopharmacology (Berlin). 118:1995;42-51.
5. Beardsley P.M., Balster R.L. Evaluation of antagonists of the discriminative stimulus and response rate effects of phencyclidine. J. Pharmacol. Exp. Ther. 244:1988;34-40.
6. Beardsley P.M., Balster R.L., Salay J.M. Separation of the response rate and discriminative stimulus effects of phencyclidine. Training dose as a factor in phencyclidine-saline discrimination J. Pharmacol. Exp. Ther. 241:1987;159-165.
7. Bespalov A.Y., Beardsley P.M., Balster R.L. Interactions between N-methyl-D-aspartate receptor antagonists and the discriminative stimulus effects of morphine in rats. Pharmacol. Biochem. Behav. 60:1998;507-517.
8. Browne R.G., Welch W.M. Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science. 217:1982;1157-1159.
9. Colpaert F.C., Koek W. Mechanisms of drug responding in drug discrimination. Behav. Pharmacol. (Suppl.). 5:1994;8.
10. Contreras P.C., Rafferty M.F., Lessor R.A., Rice K.C., Jacobson A.E. A specific alkylating ligand for phencyclidine (PCP) receptors antagonizes PCP behavioral effects. Eur. J. Pharmacol. 111:1985;405-406.
11. Corbett R. Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol. Biochem. Behav. 51:1995;561-564.
12. Domino E.F. Chemical dissociation of human awareness. Focus on non-competitive NMDA receptor antagonists J. Psychopharmacol. 6:1992;418-424.
13. Domino E.F. History and pharmacology of PCP and PCP-related analogs. J. Psychedel. Drugs. 12:1980;223-227.
14. Geter-Douglass B., Witkin J.M. Discriminative stimulus effects of low affinity non-competitive NMDA antagonists. Harris L.S. Problems of drug dependence 1995 NIDA Monograph 162. 1996;356 U.S. Government Printing Office, Washington, DC.
15. Geter-Douglass B., Witkin J.M. Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology (Berlin). 133:1997;43-50.
16. Grant K.A., Colombo G., Grant J., Rogawski M.A. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology. 35:1996;1709-1719.
17. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B., Meissner I., Murphy D., LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke. 26:1995;602-605.
18. Herling S., Coale E.H. Jr., Hein D.W., Winger G., Woods J.H. Similarity of the discriminative stimulus effects of ketamine, cyclazocine, and dextrorphan in the pigeon. Psychopharmacology (Berlin). 73:1981;286-291.
19. Hundt W., Hölter S.M., Spanagel R. Discriminative stimulus effects of glutamate release inhibitors in rats trained to discriminate ethanol. Pharmacol. Biochem. Behav. 59:1998;691-695.
20. Iversen L.L., Lees K.R. Excitatory amino acid antagonists. Baillière's Clin. Anaesthesiol. 10:1996;481-496.
21. Jackson A., Sanger D.J. Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-D-aspartate receptors? Psychopharmacology (Berlin). 96:1988;87-92.
22. Järbe T.U.C., Johansson J.O., Henriksson B.G. Drug discrimination in rats. The effects of phencyclidine and ditran Psychopharmacologia. 42:1975;33-39.
23. Jin J.J., Yamamoto T., Watanabe S. The involvement of σ receptors in the choice reaction performance deficits induced by phencyclidine. Eur. J. Pharmacol. 319:1997;147-152.
24. Jones H.E., Li H., Balster R.L. Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol. Biochem. Behav. 59:1998;413-418.
25. Kleven, M. S.; Colpaert, F. C.; Koek, W.: The σ-selective ligand NE-100 attenuates the effects of high doses of dizocilpine in rats trained to discriminate dizocilpine from saline. EBPS meeting abstract, Brno; 1998.
26. Koek W., Woods J.H. Partial generalization in pigeons trained to discriminate morphine from saline. Drug. Dev. Res. 16:1989;169-181.
27. Koek W., Colpaert F.C., Vignon J. Effects of phencyclidine-type drugs in rats discriminating fentanyl from saline. Pharmacological and behavioral characterizations of intermediate levels of drug lever selection J. Pharmacol. Exp. Ther. 264:1993;746-756.
28. Koek W., Kleven M.S., Colpaert F.C. Effects of the NMDA antagonist, dizocilpine, in various drug discriminations. Characterization of intermediate levels of drug lever selection Behav. Pharmacol. 6:1995;590-600.
29. Koek W., Woods J.H. 2-Amino-6-trifluoromethoxy benzothiazole (PK 26124), a proposed antagonist of excitatory amino acid neutrotransmission, does not produce phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. Neuropharmacology. 27:1988;771-775.
30. Koek W., Woods J.H., Calpaert F.C. N-methyl-D-aspartate antagonism and phencyclidine-like activity. A drug discrimination analysis J. Pharmacol. Exp. Ther. 253:1990;1017-1025.
31. Koek W., Woods J.H., Jacobson A.E., Rice K.C., Lessor R.A. Metaphit, a proposed phencyclidine receptor acylator phencyclidine-like behavioral effects and evidence of absence of antagonist activity in pigeons and in rhesus monkeys. J. Pharmacol. Exp. Ther. 237:1986;386-392.
32. Kornhuber J., Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism. Implications for neuroprotective pharmacotherapy Biol. Psychiatry. 41:1997;135-144.
33. Kristensen J.D., Svensson B., Gordh T. Jr. The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain. 51:1992;249-253.
34. Krystal J.H., Petrakis I.L., Webb E., Cooney N.L., Karper L.P., Namanworth S., Stetson P., Trevisan L.A., Charney D.S. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch. Gen. Psychiatry. 55:1998;354-360.
35. Leach M.J., Baxter M.G., Critchley M.A.E. Neurochemical and behavioral aspects of lamotrigine. Epilepsia. 32:1991;S4-S8.
36. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor. Structure-activity relationships and therapeutic potential J. Med. Chem. 37:1994;4053-4067.
37. Mansbach R.S., Balster R.L. Pharmacological specificity of the phencyclidine discriminative stimulus in rats. Pharmacol. Biochem. Behav. 39:1991;971-975.
38. Mcallister K.H. A time-activity baseline to measure pharmacological and non-pharmacological manipulations of PCP-induced activity in mice. Psychopharmacology (Berlin). 134:1997;157-163.
39. Muir K.W., Grosset D.G., Gamzu E., Lees K.R. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br. J. Clin. Pharmacol. 38:1994;33-38.
40. Muir K.W., Grosset D.G., Lees K.R. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clin. Neuropharmacol. 20:1997;311-321.
41. Nicholson K.L. Jones, H. E.; Balster, R. L. Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine Behav. Pharmacol. 9:1998;231-243.
42. Okuyama S., Imagawa Y., Ogawa S., Araki H., Ajima A., Tanaka M., Muramatsu M., Nakazato A., Yamaguchi K., Yoshida M, Otomo S. NE-100, a novel sigma receptor ligand. In vivo tests Life Sci. 53:1993;PL285-PL290.
43. Okuyama S., Imagawa Y., Sakagawa T., Nakazato A., Yamaguchi K., Katoh M., Yamada S., Araki H., Otomo S. NE-100, a novel sigma receptor ligand. Effect on phencyclidine-induced behaviors in rats, dogs and monkeys Life Sci. 55:1994;PL133-PL138.
44. Okuyama S., Imagawa Y., Tomisawa K. Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice. Neuropharmacology. 35:1996;467-474.
45. Okuyama S., Ogawa S., Nakazato A., Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci. Lett. 189:1995;60-62.
46. Patat A., Molinier P., Hergueta T., Brohier S., Zieleniuk I., Danjou P., Warot D., Puech A. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist. Int. Clin. Psychopharmacol. 9:1994;155-162.
47. Popik P., Layer R.T., Fossom L.H., Benveniste M., Geter-Douglass B., Witkin J.M., Skolnick P. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:1995;753-760.
48. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology (Berlin). 114:1994;672-674.
49. Rao T.S., Contreras P.C., Cler J.A., Emmett M.R., Mick S.J., Iyengar S., Wood P.L. Clozapine attenuates N-methyl-D-aspartate receptor complex-mediated responses in vivo - Tentative evidence for a functional modulation by a noradrenergic mechanism. Neuropharmacology. 30:1991;557-565.
50. Reimherr F.W., Wood D.R., Wender P.H. The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol. Bull. 22:1986;237-242.
51. Reiderer P., Lange K.W., Kornhuber J., Danielczyk W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet. 338:1991;1022-1023.
52. Rockstroh S., Emre M., Tarral A., Pokorny R. Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans. Psychopharmacology (Berlin). 124:1996;261-266.
53. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists. channel blockers and 2, 3-benzodiazepines Trends Pharmacol. Sci. 14:1993;325-331.
54. Sanger D.J., Terry P., Katz J.L. Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav. Pharmacol. 3:1992;265-268.
55. Sathananthan G.L., Sanghvi I., Phillips N., Gershon S. MJ 9022. Correlation between neuroleptic potential and stereotypy Curr. Ther. Res. 18:1975;701-705.
56. Shelton K.L., Balster R.L. Ethanol drug discrimination in rats. Substitution with GABA agonists and NMDA antagonists Behav. Pharmacol. 5:1994;441-450.
57. Sveinbjornsdottir S., Sander J.W., Upton D., Thompson P.J., Patsalos P.N., Hirt D., Emre M., Lowe D., Duncan J.S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy. Res. 16:1993;165-174.
58. Tricklebank M.D., Singh L., Oles R.J., Wong E.H., Iversen S.D. A role for receptors of N-methyl-D-aspartic acid in the discriminative stimulus properties of phencyclidine. Eur. J. Pharmacol. 141:1987;497-501.
59. Troupin A.S., Mendius J.R., Cheng F., Risinger M.W. Mk-801. Meldrum B., Porter R. New anticonvulsant drugs. 1986;191-201 John Libbey, London.
60. VonVoigtlander P.F., Tang A.H., Ochoa M.C., Franklin S.R., Triezenberg H.J. A search for phencyclidine antagonists. Kamenka J.-M., Domino E.F., Geneste P. Phencyclidine and related arylcyclohexylamines. Present and future applications:1983;627-638 NPP Books, Ann Arbor, MI.
61. Willetts J., Balster R.L. Phencyclidine-like discriminative stimulus properties of MK-801 in rats. Eur. J. Pharmacol. 146:1988;167-169.
62. Willetts, J.; Balster, R. L.; Leander, J. D.: The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. (Special Report 1991):62-67; 1991.
63. Witkin, J. M.; Geter-Douglass, B.: Acri, J. B.; Deboer, P.; Wikstrom, H.: Interactions of the selective dopamine D3 agonist, PD 128,907 with dizocilpine (MK-801): Behavioral and neurochemical effects. Behav. Pharmacol. 7(Suppl. 1):122; 1996.
64. Woods J.H. Alteration by other drugs of phencyclidine's discriminative performance in the rhesus monkey. Kamenka J.-M., Domino E.F., Geneste P. Phencyclidine and related arylcyclohexylamines. Present and future applications:1983;337-345 NPP Books, Ann Arbor, MI.
65. Woods J.H., Koek W., France C.P., Moerschbaecher J.M. Behavioural effects of NMDA antagonists. Meldrum B.S. Excitatory amino acid antagonists. 1991;237-264 Blackwell, London.
66. Yenari M.A., Bell T.E., Kotake A.N., Powell M., Steinberg G.K. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin. Neuropharmacol. 21:1998;28-34.
67. Young B.K., Camicioli R., Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging. 10:1997;367-383.